Kimberly-Clark Form 483: Should Have Retested Lots

The GMP Letter
Kimberly-Clark received a Form 483 after investigators from the FDA’s Dallas district office found it did not retest product lots manufactured on two lines that were involved in earlier findings of contamination.

To View This Article:


Subscribe To The GMP Letter

Buy This Article Now

Add this article to your cart for $135.00